Biogen

-$1.60 (-0.59%) Today
+$0.37 (+0.14%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.

CEO
Michel Vounatsos
Employees
9,100
Headquarters
Cambridge, Massachusetts
Founded
1978

BIIB Key Statistics

Market Cap
39.96B
Price-Earnings Ratio
21.63
Dividend Yield
—
Average Volume
958.62K
High Today
$271.66
Low Today
$266.30
Open Price
$270.00
Volume
1.80M
52 Week High
$468.55
52 Week Low
$223.25

BIIB News

Reuters11h

Biogen sales face pressure from slow uptake of Alzhiemer's drug

Aduhelm, Biogen's controversial recently approved drug for early Alzheimer's disease, is seen at Butler Hospital, one of the clinical research sites in Providen
Benzinga12h

Expert Ratings For Biogen - Biogen Idec

Over the past 3 months, 13 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks
Benzinga14h

Earnings Outlook For Biogen

Biogen(NASDAQ:BIIB) is set to give its latest quarterly earnings report on Wednesday, 2021-10-20. Here's what investors need to know before the announcement. A

BIIB Earnings

$0.00
$3.42
$6.84
$10.26
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
$4.14 per share
Actual
Available Oct 20, Pre-Market

More BIIB News

Barron'sOct 18

Biogen Stock Drops as ALS Trial Fails. Ionis Is Getting Hit Even Harder.

MarketWatch Shares of Biogen were down 0.6% in premarket trading on Monday, the day after the company said an experimental amyotrophic lateral sclerosis (ALS)
MarketWatchOct 18

Ionis Pharma Shares Drop 12% After Tofersen Study Misses Primary Endpoint

By Chris Wack Ionis Pharmaceuticals Inc. shares fell 12% to $30.90 after the company said a study for tofersen missed its primary endpoint. The company said i
MarketWatchOct 18

Biogen says ALS drug did not meet primary endpoint in Phase 3 clinical trial

Shares of Biogen BIIB, -1.43% were down 0.6% in premarket trading on Monday, the day after the company said an experimental amyotrophic lateral sclerosis (ALS)
Fox BusinessOct 17

In quiet debut, Alzheimer’s drug finds questions, skepticism

The first new Alzheimer’s treatment in more than 20 years was hailed as a breakthrough when regulators approved it more than four months ago, but its rollout ha
ReutersOct 17

Biogen trial of ALS drug fails main goal, but company says data are encouraging

By Deena Beasley Oct 17 (Reuters) - A late-stage trial of Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) fail
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure